Items where authors include "Denton, C.P."

Article

Di Donato, S. orcid.org/0000-0003-1256-0761, Ross, R., Karanth, R. et al. (7 more authors) (2025) Serum Type I Interferon Score predicts clinically meaningful disease progression in limited cutaneous Systemic Sclerosis. Arthritis & Rheumatology. ISSN 2326-5191

Bjørkekjær, H.J., Bruni, C., Broch, K. et al. (60 more authors) (2025) A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. Rheumatology. keaf053. ISSN 1462-0324

Roth, E., Bruni, C., Petelytska, L. et al. (244 more authors) (2025) Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology. keaf016. ISSN 1462-0324

Del Galdo, F. orcid.org/0000-0002-8528-2283, Lescoat, A., Conaghan, P.G. orcid.org/0000-0002-3478-5665 et al. (23 more authors) (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Annals of the Rheumatic Diseases, 84 (1). pp. 29-40. ISSN 0003-4967

Ross, R.L., Caballero-Ruiz, B., Clarke, E.L. et al. (11 more authors) (2024) Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of SSc (VEDOSS). Rheumatology. keae698. ISSN 1462-0324

Spierings, J., Welsing, P.M.J., Colak, S. et al. (7 more authors) (2024) Self-reported skin severity and quality of life in systemic sclerosis: multicentre validation of PASTUL. Rheumatology. keae561. ISSN 1462-0324

Denton, C.P., De Lorenzis, E., Roblin, E. et al. (27 more authors) (2024) The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology. keae394. ISSN 1462-0324

Denton, C.P., De Lorenzis, E., Roblin, E. et al. (27 more authors) (2024) The 2024 British Society for Rheumatology guideline for management of systemic sclerosis—executive summary. Rheumatology. keae390. ISSN 1462-0324

Khanna, D., Denton, C.P., Assassi, S. et al. (12 more authors) (2024) A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale. Clinical and Experimental Rheumatology, 42 (8). pp. 1635-1644. ISSN 0392-856X

Álvarez-Hernández, M.P. orcid.org/0000-0002-9972-1312, Allanore, Y., Andrade, I. et al. (9 more authors) (2024) Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologists. Journal of Scleroderma and Related Disorders. ISSN 2397-1983

Tornling, G., Edenius, C., Pauling, J.D. et al. (16 more authors) (2024) A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's. Rheumatology. keae049. ISSN 1462-0324

Lescoat, A., Bellando-Randone, S., Campochiaro, C. et al. (9 more authors) (2023) Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine. The Lancet Rheumatology, 5 (11). e683-e694. ISSN 2665-9913

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 62 (9). pp. 3133-3138. ISSN 1462-0324

Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D. et al. (19 more authors) (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 62 (9). pp. 3133-3138. ISSN 1462-0324

Spiera, R. orcid.org/0000-0003-2911-6800, Kuwana, M. orcid.org/0000-0001-8352-6136, Khanna, D. orcid.org/0000-0003-1412-4453 et al. (28 more authors) (2023) Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 75 (9). pp. 1608-1618. ISSN 2326-5191

Lepri, G., Hughes, M., Allanore, Y. et al. (8 more authors) (2023) The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution. The Lancet Rheumatology, 5 (7). e422-e425. ISSN 2665-9913

Denton, C.P. orcid.org/0000-0003-3975-8938, De Lorenzis, E., Roblin, E. et al. (27 more authors) (2023) Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (1). rkad022. ISSN 2514-1775

Denton, C.P. orcid.org/0000-0003-3975-8938, del Galdo, F. orcid.org/0000-0002-8528-2283, Khanna, D. et al. (12 more authors) (2023) Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 62 (1). pp. 234-242. ISSN 1462-0324

Kakkar, V., Assassi, S., Allanore, Y. et al. (4 more authors) (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6). pp. 357-364. ISSN 1040-8711

Hughes, M., Allanore, Y., Baron, M. et al. (13 more authors) (2022) Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology, 4 (11). e795-e803. ISSN 2665-9913

Lazzaroni, M-G., Marasco, E., Campochiaro, C. et al. (30 more authors) (2021) The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology, 60 (11). pp. 5028-5041. ISSN 1462-0324

Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983

Bageghni, S.A., Hemmings, K.E., Yuldasheva, N.Y. et al. (11 more authors) (2019) Fibroblast-specific deletion of IL-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight, 4 (17). ISSN 2379-3708

Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967

Conference or Workshop Item

DI Donato, S., Ross, R., Karanth, R. et al. (6 more authors) (2024) OP0314 Interferon score as a novel trial enrichment tool to predict clinical outcomes in patients with limited cutaneous systemic sclerosis. In: EULAR 2024 European Congress of Rheumatology, 12-15 Jun 2024, Vienna, Austria.

Roth, E., Bruni, C., Petelytska, L. et al. (18 more authors) (2024) POS0230 Characteristics and disease course of SSc-ILD patients with gastroesophageal reflux – an analysis of the EUSTAR cohort. In: EULAR 2024 European Congress of Rheumatology, 12-15 Jun 2024, Vienna, Austria.

Spierings, J., Ong, V.H., Welsing, P.M.J. et al. (5 more authors) (2024) P139 Self-assessment of scleroderma skin: validation of the PASTUL questionnaire. In: British Society for Rheumatology Annual Conference 2024, 24-26 Apr 2024, Liverpool.

De Lorenzis, E., Kakkar, V., Di Donato, S. et al. (13 more authors) (2023) AB0881 clinical trajectories of multifactorial hand function deterioration in systemic sclerosis. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Ross, R., Clarke, E., Merchant, W. et al. (8 more authors) (2023) POS0146 biosamples from vedoss patients show classic pathological signs of scleroderma:opportunity for a biological diagnosis of disease. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Del Galdo, F. orcid.org/0000-0002-8528-2283, Lescoat, A., Conaghan, P.G. et al. (24 more authors) (2023) OP0234 2023 Update Of Eular Recommendations For The Treatment Of Systemic Sclerosis. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 154-155.

Bruni, C., Tofani, L., Fretheim, H. et al. (55 more authors) (2023) OP0238 Immunosuppression With Targeted Dmards Reduces Morbidity And Mortality In Pre-Capillary Pulmonary Hypertension Associated With Systemic Sclerosis: A Eustar Analysis. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 157-159.

Lescoat, A., Chen, Y., Murphy, S.L. et al. (22 more authors) (2023) POS1258 Results from a nominal group technique exercise for the creation of a combined response index for limited cutaneous systemic sclerosis: The CRISTAL project. In: Annals of the Rheumatic Diseases. EULAR 2023 - European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 971-972.

Ross, R.L., Clarke, E., Merchant, W. et al. (8 more authors) (2023) P162 Biosamples from VEDOSS patients show classic pathological signs of Scleroderma: Opportunity for a biological diagnosis of disease. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 2023-04-24 2023-04-26, Manchester, UK. Oxford University Press .

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.